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Background: Ceramide is a bioeffector that mediates various cellular processes, including apoptosis. However, the
mechanism underlying ceramide function in apoptosis is apparently cell type-dependent and is not well-understood.
We aimed at identifying molecular targets of ceramide in metastatic human colon and breast cancer cells, and
determining the efficacy of ceramide analog in suppression of colon and breast cancer metastasis.
Methods: The activity of and mechanism underlying ceramide as a cytotoxic agent, and as a sensitizer for Fas-mediated
apoptosis was analyzed in human cell lines established from primary or metastatic colon and breast cancers. The
efficacy of ceramide analog LCL85 in suppression of metastasis was examined in preclinical mouse tumor models.
Results: Exposure of human colon carcinoma cells to ceramide analog LCL85 results in apoptosis in a dose-dependent
manner. Interestingly, a sublethal dose of LCL85 increased C16 ceramide content and overcame tumor cell resistance to
Fas-mediated apoptosis. Subsequently, treatment of tumor cells with exogenous C16 ceramide resulted in increased
tumor cell sensitivity to Fas-mediated apoptosis. LCL85 resembles Smac mimetic BV6 in sensitization of colon carcinoma
cells to Fas-mediated apoptosis by inducing proteasomal degradation of cIAP1 and xIAP proteins. LCL85 also decreased
xIAP1 and cIAP1 protein levels and sensitized metastatic human breast cancer cells to Fas-mediated apoptosis. Silencing
xIAP and cIAP1 with specific siRNAs significantly increased the metastatic human colon carcinoma cell sensitivity to
Fas-mediated apoptosis, suggesting that IAP proteins mediate apoptosis resistance in metastatic human colon
carcinoma cells and ceramide induces IAP protein degradation to sensitize the tumor cells to apoptosis induction.
Consistent with its apoptosis sensitization activity, subtoxic doses of LCL85 suppressed colon carcinoma cell metastatic
potential in an experimental lung metastasis mouse model, as well as breast cancer growth and spontaneous lung
metastasis in an orthotopic breast cancer mouse model.
Conclusion: We have identified xIAP and cIAP1 as molecular targets of ceramide and determined that ceramide analog
LCL85 is an effective sensitizer in overcoming resistance of human cell lines established from metastatic colon and
breast cancers to apoptosis induction to suppress metastasis in vivo.
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Fas (also termed CD95 and TNFRSF6) is a member of
the TNF death receptor superfamily. Despite other “non-
apoptotic” cellular responses emanating from its signaling,
the major and best known function of Fas is apoptosis. Fas
is expressed on tumor cell surface, and its physiological
ligand, FasL, is expressed on activated T cells and NK
cells. Compelling experimental data from both human
cancer patients and mouse tumor models indicate that the
Fas-mediated apoptosis pathway plays a key role in
suppression of cancer development and in host cancer
immunosurveillance [1-3]. Furthermore, human cancer
genomics data indicate that Fas is not significantly focally
amplified across a dataset of 3131 tumors, but is signifi-
cantly focally deleted across the entire dataset of these 3131
tumors, including human colorectal cancer (http://www.
broadinstitute.org/tumorscape/pages/portalHome.jsf).
These data thus strongly suggest that Fas functions as a
tumor suppressor.
To avoid apoptosis, tumor cells tend to down-regulate
Fas expression or alter the expression of key mediators of
the Fas-mediated apoptosis signaling pathway to advance
the disease [4-6]. This is well-supported by the pheno-
menon that resistance to apoptosis, including Fas-mediated
apoptosis, is a hallmark in human cancers [5,7], particularly
in metastatic human colorectal cancer [2,3,8] and breast
cancer [9]. Therefore, therapeutic intervention of tumor
cell resistance to Fas-mediated apoptosis potentially
represents an effective approach to render tumor cell
sensitivity to FasL+ cytotoxic T lymphocytes (CTL) of
the host immunosurveillance system or to CTL-based
adoptive cancer immunotherapy to suppress tumor pro-
gression [1,5,10].
During the last decade, sphingolipids have emerged as
bioeffectors that mediate various cellular processes,
including proliferation and apoptosis of cancer cells
[11-14]. Sphingolipid deregulation, namely the balance
between ceramide and sphingosine 1-phosphate, has
been implied as a key factor in tumor pathogenesis and
apoptosis resistance [13,15]. Although it has been de-
monstrated that de novo-generated ceramides may
confer certain types of tumor cells with resistance to
apoptosis [16], ceramide, the central molecule of the
sphingolipid metabolism pathway, generally promotes
apoptosis [17-19]. The role of ceramide in Fas-mediated
apoptosis has also been well-documented [20]. Ceramide
enables Fas receptor to cluster to increase Fas-mediated
apoptosis [21], and modulate Fas receptor activation
[22,23]. Ceramide has also been shown to regulate
apoptosis through modulating key molecules of the Fas-
mediated apoptosis pathways [22,24-26]. Elevation of
acid ceramidase, the enzyme that converts ceramide to
sphingosine and subsequently sphingosine 1-phosphate,
has been frequently observed in apoptosis-resistantcancer cells, including metastatic colon carcinoma cells
[17,27,28]. These observations thus suggest that targeting
ceramide metabolism to increase ceramide accumulation
might be an effective approach to overcome cancer cell
resistance to Fas-mediated apoptosis. In this study, we
demonstrated that aromatic ceramide analog LCL85 ef-
fectively overcomes metastatic human colon and breast
cancer cell resistance to Fas-mediated apoptosis at least
partially through inducing proteasomal degradation of
cIAP1 and xIAP in vitro. More significantly, we demon-
strated that LCL85 effectively suppresses colon and breast
cancer metastasis in vivo. Our data determined that
LCL85 is potentially an effective apoptosis sensitizer
that warrants further development as an adjunct agent




BALB/c mice were obtained from National Cancer Institute
(Frederick, MD). All studies are approved by the Georgia
Regents University Institutional Animal Care and Use
Committee (Protocol# 2011–0365).
Cell lines
All human cell lines established from primary and meta-
static colon and breast cancer tissues (referred to as pri-
mary and metastatic human colon and breast cancer cell
lines), and mouse breast cancer cell line 4 T1 were
obtained from American Type Culture Collection (ATCC)
(Manassas, VA). ATCC characterizes these cells by
morphology, immunology, DNA fingerprint, and cyto-
genetics. Murine Colon26 cells were kindly provided
by Dr. William E. Carson, III (Ohio State University,
Columbus, OH).
Reagents
BV6 was kindly provided by Genentech. Ceramide analogs
B13 and LCL85 were synthesized by Lipidomics Shared
Resource at Medical University of South Carolina [29]. FasL
(Mega-Fas Ligand®) was provided by Drs. Steven Butcher
and Lars Damstrup (Topotarget A/S, Denmark). C16-
ceramide was obtained from Santa Cruz Biotech, and was
dissolved in dodecane:ethanol (2:98, v/v; 0.05% final con-
centration) as described [21]. MG-132 and Z-VAD-FMK
were obtained from Enzo Life Sciences (Farmingdale, NY).
Western blotting analysis
Western blotting analysis was performed as previously
described [30]. Anti-cIAP1 was obtained from R&D Sys-
tem (Minneapolis, MN). Anti-Bax and cIAP2 antibodies
were obtained from Santa Cruz Biotech (Santa Cruz,
CA). Anti-Bak and xIAP antibodies were obtained from
Cell Signaling Biotech (Danvers, MA), anti-Bcl-2, and
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(San Diego, CA), and anti-β-actin was obtained from
Sigma (St Louis, MO).
Cell viability assays
Cell viability assay was carried out as previously described
[31] using the MTT cell proliferation assay kit (ATCC,
Manassas, VA).
Apoptosis analysis
Cells were treated with BV6, LCL85, or C16 ceramide for
1 h, followed by incubation with FasL for approximately
24 h. Apoptosis analysis was as previously described [32].
Briefly, cells were then collected and incubated with
propidium iodide (PI) and Annexin V (Biolegend), and
analyzed by flow cytometry. The percentage of apoptosis
was calculated by the formula: % apoptosis = % PI and
AnnexinV double positive cells with FasL - % PI and
Annexin V double positive cells without FasL.
Measurement of endogenous ceramide level
Cellular levels of endogenous ceramides were measured
by Lipidomics Shared Resource, MUSC, using high-
performance liquid chromatography-mass spectrometry
approach (LC-MS/MS) as previously described. Ceramide
levels were normalized to the total cellular protein
contents.
Cell surface protein analysis
Tumor cells were stained with anti-Fas (BD biosciences),
anti-FasL (BD biosciences), or anti-CD8 (Biolegend, San
Diego, CA) mAbs. Isotype-matched control IgG (Biolegend)
was used as a negative control. The stained cells were ana-
lyzed by flow cytometry. For FasL protein analysis, mouse
lungs were digested in collagenase solution to make a single
cell suspension. The cell suspension was stained with
PE-conjugated FasL (BD Biosciences) or FITC-conjugated
CD8 mAb, or both mAbs and analyzed by flow cytometry.
Gene silencing
RNAi-based silencing of gene expression in tumor cells was
done as previously described [33]. Briefly, SW620 cells were
transiently transfected with scramble siRNA (Dharmacon),
and human xIAP- and cIAP1-specific siRNAs (Santa Cruz
Biotech), respectively, using Lipofectamine 2000 (Invi-
trogen) for approximately 24 h. Cells were then harvested.
Part of the cells were used for RT-PCR analysis of xIAP
and cIAP expression. Another part of the cells were cultured
in the absence or presence of FasL for approximately
24 h and then analyzed for apoptosis.
Liver toxicity analysis
LCL85 was injected to BALB/c mice (5 mg/kg body
weight) i.v. Peripheral blood was collected from mice3 days later using Multivette 600 Z-gel tubes (SARSTEDT).
Serum was separated by centrifugation and measured
for complete liver enzyme profile at Georgia Laboratory
Animal Diagnostic Service (Athens, GA).
Colon cancer experimental lung metastasis
Colon 26 cells (1.5×105 cells/mouse) were injected to
BALB/c mice iv. LCL85 (0, 1 and 5 mg/kg body weight)
was injected iv to tumor-bearing mice at days 3, 6, 9 and 12
after tumor injection. Mice were sacrificed at day 14 and
analyzed for lung metastasis as previously described [34].
Breast cancer spontaneous lung metastasis
4 T1 cells (1×104 cells/mouse) were injected to the
mammary fat pad. LCL85 (2.5 mg/kg body weight) was
injected to the tumor-bearing mice at days 7, 10, 13, and
16 after tumor injection. Mice were sacrificed 29 days
after tumor injection, and analyzed for primary tumor
growth and lung metastasis. To determine the efficacy
of LCL85 on metastasis, 4 T1 cells (1×104 cells/mouse)
were injected to the mammary fat pad. Primary tumors
were surgically removed 16 days later. Mice were treated
with LCL85 (2.5 mg/kg body weight) at days 10, 13, and
16 after surgery. Mice were sacrificed and analyzed for
lung metastasis 19 days after surgery.
Statistical analysis
Where indicated, data were represented as the mean ± SD.
Statistical analysis was performed using two-sided t test,
with p-values < 0.05 considered statistically significant.
Results
Ceramide analog effectively sensitizes metastatic human
colon and breast cancer cell apoptosis resistance
Ceramide analogs of B13 and LCL85 were tested for their
cytotoxicity against human colon carcinoma cell lines
(6 primary and 5 metastatic human colon cancer cell
lines). Cell growth inhibition assays indicated that B13
and LCL85 are both cytotoxic at high doses (Figure 1).
LCL85 represents a unique compound since it is highly
cytotoxic at high doses, but exhibited almost no cytoto-
xicity at low doses (Figure 1B). Because our objective was
to test the hypothesis that ceramide analogs are effective
apoptosis sensitizers for Fas-mediated apoptosis in human
colon carcinoma cells, we chose LCL85 for this study.
Next, eleven human colon carcinoma cell lines were cul-
tured in the presence of a sublethal dose of LCL85 (5 μM)
and various doses of FasL, and analyzed for tumor cell
viability. Four of the 6 primary colon carcinoma cell lines
(SW480, HT29, HCT116 and LS174T) are highly sensitive
to FasL-induced apoptosis, and LCL85 exhibited minimal
or no sensitization effects on these 4 sensitive cell lines
(Figure 2A). On the other hand, the other 2 primary
























































Figure 1 Cytotoxicity of ceramide analogs to human colon carcinoma cells. A & B. Eleven human colon carcinoma cell lines were cultured
with B13 (A) and LCL85 (B) at the indicated doses for 24 h, respectively. Cell growth rates were measured by MTT assays. The cell growth rates in
the control groups (without ceramide analogs) were arbitrarily set as 100%. Column, mean; bar, SD.
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only exhibited minimal or no sensitization effects on these
2 cell lines (Figure 2A). One of the 5 metastatic human
colon carcinoma cell lines (T84) is sensitive to FasL-
induced apoptosis, but 4 of the 5 metastatic human colon
carcinoma cell lines (SW620, LS174T, Colo201 and
Colo205) are resistant to Fas-mediated apoptosis. A sub-
lethal dose of LCL85 significantly increased these 4 meta-
static human colon carcinoma cell lines to FasL-induced
apoptosis (Figure 2B). In summary, our data demonstrated
that a sublethal dose of LCL85 is effective in sensitizing
the apoptosis-resistant human colon carcinoma cells to
Fas-mediated apoptosis.
Next, we used SW620 and LS411N cells to determine
whether the above observed tumor cell growth inhi-
bition is due to apoptosis. SW620 and LS411N cells
were cultured in the presence of LCL85 and FasL, andanalyzed for apoptosis. Staining cells with Annexin V
and PI revealed that LCL85 induces apoptosis of SW620
and LS411N cells in a dose-dependent manner. However,
LCL85 alone at low doses only induced a small degree of
apoptosis (Figure 2C). In contrast, a sublethal dose of
LCL85 dramatically increased SW620 and LS411N cell
sensitivity to FasL-induced apoptosis (Figure 2C & D).
To determine whether LCL85-sensitized apoptosis is
tumor type-dependent, we also tested the effects of LCL85
on metastatic human breast cancer cells. MDA-MB-231
cells were treated with various doses of LCL85 in the
absence or presence of FasL and analyzed for apoptosis.
As in the human colon carcinoma cells, LCL85 induced
MDA-MB-231 apoptosis in a dose-dependent manner,
albeit at a low degree (Figure 3). MDA-MB-231 cells are
resistant to FasL-induced apoptosis, and LCL85 is effective
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Figure 2 (See legend on next page.)
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Figure 2 A suboptimal dose of ceramide analog LCL85 overcomes metastatic human colon carcinoma cell resistance to Fas-mediated
apoptosis. A & B. Sensitization of primary (A) and metastatic (B) human colon carcinoma cells to FasL-induced growth inhibition by LCL85. Six
primary human colon carcinoma cell lines (A) and 5 metastatic human colon carcinoma cell lines (B) were cultured in the absence or presence
of a sublethal dose of LCL85 (5 μM) and FasL at the indicated concentrations for 24 h. Cell growth rate was measured by MTT assays. *p < 0.05;
**p < 0.01. C & D. SW620 (C) and LS411N (D) cells were incubated with LCL85 at the indicated dose for 1 h and then cultured in the absence or
presence of FasL (250 ng/ml) overnight. Cells were stained with Annexin V and PI and analyzed by flow cytometry. Cell death is indicated at the
top right corner of each plot. Percentage of FasL-induced cell death is calculated by the formula: % Annexin V+ and PI+ cells in the presence of
FasL- % Annexin V+ and PI+ cells in the absence of FasL, and presented at the right.
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tions thus suggest that a sublethal dose of ceramide analog
LCL85 is a potent apoptosis sensitizer.
LCL85 increases cellular C16 ceramide level to sensitize
colon carcinoma cells to apoptosis
We next treated SW620 cells with a sublethal dose of
LCL85 and measured the level of cellular ceramides and
ceramide metabolites. Treatment of LCL85 increased C16
ceramide level in the tumor cells (Figure 4A), suggesting
that LCL85 might increase C16 ceramide level to sensitize
human colon carcinoma cells to Fas-mediated apoptosis.
To test this hypothesis, SW620 cells were cultured in the
presence of exogenous C16 ceramide and FasL. Although
exogenous C16 ceramide directly induced apoptosis in a
dose-dependent manner, albeit at a low level, exogenous
C16 ceramide significantly increased SW620 cell sensi-
tivity to FasL-induced apoptosis (Figure 4B & C). There-
fore, LCL85 sensitizes human colon carcinoma cells to
Fas-mediated apoptosis at least partially through increa-
sing C16 ceramide level in the tumor cells.
xIAP and cIAP1 are molecular targets of LCL85
We next sought to identify the targets of ceramide. To
determine whether LCL85 alters Fas expression, we
treated SW620 cells with LCL85 and analyzed cell surface
Fas protein levels. Flow cytometry analysis indicated thatLCL85 (μ
4.5% 7.8% 5.4%
2.8% 6.3% 12.9
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Figure 3 LCL85 overcomes metastatic breast cancer cell resistance to
LCL85 at the indicated doses in the absence or presence of FasL (250 ng/m
and analyzed by flow cytometry. Cell death was indicated at the top rightLCL85 does not increase cell surface Fas protein level
(Figure 5A). As a positive control, Vorinostat significantly
increased cell surface Fas protein level in SW620 cells [34]
(Figure 5A & B). As a complimentary approach, SW620
cells were treated with C16 ceramide and analyzed for cell
surface Fas expression level. C16 ceramide treatment did
not alter cell surface Fas protein level (Figure 5C & D).
The above observations that LCL85 does not alter Fas
level suggests that LCL85 may target mediators of the
Fas-mediated apoptosis signaling pathways. IAPs are po-
tent inhibitors of apoptosis, including Fas-mediated apop-
tosis [35-37]. To determine whether IAPs play a role in
metastatic human colon carcinoma apoptosis resistance,
we tested the effects of IAP-specific inhibitor BV6
on metastatic human colon carcinoma cells. The same
panel of 5 metastatic human colon carcinoma cell lines
(Figure 2B) were cultured in the presence of various doses
of BV6 and measured for growth inhibition. Like LCL85,
BV6 exhibited direct cytotoxicity in a dose-dependent
manner (Figure 6). Next, we used a sublethal dose of BV6
to determine whether BV6 sensitizes metastatic human
colon carcinoma cells to FasL-induced apoptosis. Incu-
bation of tumor cells with BV6 and FasL revealed that
BV6 significantly increases sensitivity of all 5 metastatic
human colon carcinoma cells to FasL-induced cell growth
inhibition (Figure 7A), and the growth inhibition pattern
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Figure 4 C16 ceramide sensitizes metastatic human colon carcinoma cells to Fas-mediated apoptosis. A. SW620 cells were treated with
LCL85 (5 μM) for 24 h. Cells were then lysed and measured for ceramide contents. Shown are representative results of one of two independent
measurements. B. Exogenous C16 ceramide sensitizes tumor cell to Fas-mediated apoptosis. SW620 cells were treated with C16 ceramide for 1 h
at the indicated concentrations, and then cultured in the absence or presence of FasL for approximately 24 h. Cells were stained with Annexin V
and PI and analyzed by flow cytometry. The apoptotic cell death is indicated at the top right corner of each plot. Shown are results of one of
three representative experiments. C. Quantification of apoptosis as shown in B. % FasL-induced cell death is calculated by the formula: % Annexin
V+ and PI+ cells in the presence of FasL- % Annexin V+ and PI+ cells in the absence of FasL. Column: mean; Bar: SD.
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static colon carcinoma cells to Fas-mediated apoptosis by
a mechanism similar to BV6.
BV6 targets IAP proteins to induce apoptosis
We then analyzed the effects of LCL85 on IAP proteins
in metastatic human colon carcinoma cells. SW620 cells
were treated with LCL85 and analyzed for IAP protein
levels at various time points. Among the 3 IAP proteins,
xIAP protein levels dramatically decreased 12 h after
LCL85 treatment. cIAP1 protein was also decreased,
albeit at a smaller degree. cIAP2 protein level was not
significantly changed by LCL85 treatment (Figure 7B).
To determine whether LCL85 also decreases xIAP
protein levels in metastatic human breast cancer cells,MDA-MB-231 cells were treated with LCL85, and ana-
lyzed for xIAP and cIAP protein levels. It is clear that
LCL85 decreases xIAP and cIAP1 protein levels in a
dose-dependent manner (Figure 7C). Next, SW620 cells
were cultured in the presence of a sublethal dose of BV6
(5 μM) and FasL, and analyzed for apoptosis. It is clear
that BV6 dramatically increased SW620 cell sensitivity
to FasL-induced apoptosis (Figure 7D). Our results thus
revealed that LCL85 targets xIAP and cIAP1 to sensitize
metastatic human colon carcinoma cells to Fas-mediated
apoptosis.
RT-PCR analysis indicated that LCL85 does not alter
the mRNA levels of IAP proteins in human colon car-
cinoma cells (Figure 7E). Proteasome inhibitor MG-132














































Figure 5 Ceramide does not alter Fas receptor expression. A. Cell surface Fas protein level. SW620 cells were cultured in the presence of
LCL85 (5 μM) and Vorinostat (0.5 μM) for approximately 24 h and analyzed for cell surface Fas protein level by flow cytometry. Gray area: IgG
isotype control staining, solid line: Fas-specific mAb staining. B. Quantification of Fas protein level. Cells as shown in A were quantified for Fas
protein level by mean fluorescence intensity (MFI). Column, mean; bar, SD. C. SW620 cells were cultured in the presence of C16 ceramide (2 μM)
for approximately 24 h and analyzed for cell surface Fas protein level by flow cytometry. Gray area: IgG isotype control staining, solid line:
Fas-specific mAb staining. D. Quantification of FAS MFI as shown in C. Column: mean; bar: SD.
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xIAP degradation (Figure 7F). Our data thus suggest that
LCL85 mediates proteasome-dependent degradation of
xIAP protein.
To determine the IAP protein levels in various human
colon cancer cell lines, we analyzed xIAP and cIAP1

















Figure 6 Cytotoxicity of Smac mimetic to metastatic human colon ca
cultured in the presence of various doses of BV6 for 24 h. Cell growth rates
groups (without ceramide analogs) were arbitrarily set as 100%. Column, mlines. Western blotting analysis indicated that xIAP and
cIAP1 are expressed in all 5 cell lines at a level similar
to that in LS411N and SW620 (Figure 8A).
To validate the functions of xIAP and cIAP1 in
Fas-mediated apoptosis in human colon carcinoma cells,
SW620 cells were transfected with xIAP- and cIAP1-
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Figure 7 Ceramide targets cIAP1 and xIAP to sensitize metastatic human colon and breast cancer cells to Fas-mediated apoptosis.
A. Five metastatic human colon carcinoma cell lines were cultured in the absence or presence of BV6 (5 μM) and FasL at the indicated concentrations
for 24 h. Cell growth rates were measured by MTT assays. *p < 0.05; **p < 0.01. B. SW620 cells were treated with LCL85 (5 μM) for approximately 24 h
and analyzed for IAP protein levels at the indicated time points. C. MDA-MD-231 cells treated with LCL85 at the indicated doses for approximately
24 h and analyzed for xIAP and cIAP1 protein levels by Western blotting. D. SW620 cells were incubated with BV6 (5 μM) for 1 h and then cultured in
the absence or presence of FasL overnight. Cells were stained with Annexin V and PI and analyzed by flow cytometry. The apoptotic cell death was
indicated at the top right corner of each plot. Right panel: Quantification of apoptosis. % FasL-induced cell death is calculated by the formula: %
Annexin V+ and PI+ cells in the presence of FasL - % Annexin V+ and PI+ cells in the absence of FasL. E. SW620 cells were treated with LCL85 (5 μM)
and BV6 (5 μM), respectively, for the indicated time and analyzed for expression levels of cIAP1, cIAP2 and xIAP by RT-PCR. F. SW620 cells were
pretreated with or without MG-132 (20 μM) or Z-VAD (25 μM) for 1 h followed by treatment with LCL85 for 12 h. Cells were lysed and analyzed for xIAP
protein level by Western blotting.
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(Figure 8B). Silencing xIAP or cIAP1 significantly increased
the tumor cell to FasL-induced apoptosis (Figure 8C). Our
data thus suggest that IAP proteins mediate apoptosis
resistance in metastatic human colon carcinoma cells, and
ceramide sensitizes the tumor cell to Fas-mediated apop-
tosis at least partially through inducing cIAP1 and xIAP
degradation.LCL85 also targets Bcl-xL
Ceramide has been shown to regulate Bcl-x alternative
splicing to decrease Bcl-xL level [38], and to mediate
Bak and Bax function in the intrinsic apoptosis pathway
[39-41]. In addition, Bcl-2 has been shown to activate
Bak to induce C16 ceramide accumulation [42,43]. Wethen analyzed these Bcl-2 family proteins. Western blot-
ting analysis revealed that only Bcl-xL protein level is
dramatically decreased by LCL85 in metastatic human
colon cancer cells (Figure 9A), and in the metastatic
breast cancer cells, albeit to a less degree (Figure 9B).Ceramide analog and Smac mimetic additively sensitize
metastatic human colon carcinoma cells to apoptosis
induction
Our observations that LCL85 and BV6 both target IAP
proteins suggest that they may act additively in sen-
sitization of tumor cell to apoptosis induction. To test this
hypothesis, SW620 and LS411N cells were treated with
these two agents alone or in combination, and analyzed























































































Figure 8 xIAP and cIAP1 confer metastatic human colon carcinoma cells apoptosis resistance. A. IAP protein levels in human colon
carcinoma cells. The indicated human colon carcinoma cell lines were analyzed for xIAP and cIAP protein levels by Western blotting analysis.
β-actin is used as a normalization control. B. SW620 cells were transiently transfected with scramble siRNA or xIAP- and cIAP1-specific siRNAs,
respectively overnight, and analyzed for xIAP and cIAP1 mRNA levels by RT-PCR. C. The transfected cells as shown in A were then treated with FasL
(250 ng/ml) for approximately 24 h, stained with Annexin V and PI, and analyzed by flow cytometry. D. Quantification of apoptosis. Percentage of
FasL-induced cell death as shown in B is calculated by the formula: % Annexin V+ and PI+ cells in the presence of FasL- % Annexin V+ and PI+ cells in
the absence of FasL. **p < 0.01.
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effective in sensitization of tumor cells to FasL-induced
apoptosis (Figure 10A & B), clearly, combined LCL85 and
BV6 exhibited significantly greater effects than each agent
alone on sensitization of these two tumor cells to FasL-
induced apoptosis (Figure 10A & B).Sensitivity of mouse tumor cells to LCL85-sensitized and
Fas-mediated apoptosis
We next sought to test the anti-cancer efficacy of LCL85
in preclinical mouse tumor models. First, we tested
whether LCL85 sensitizes mouse tumor cells to FasL-
induced apoptosis. Both Colon 26 and 4 T1 cells areresistant to Fas-mediated apoptosis (Figure 11A & B).
LCL85 did not exhibit sensitization activity in Colon
26 cells to FasL-induced apoptosis in our initial attempts
(Figure 11A). However, A sublethal dose of LCL85 effec-
tively overcame 4 T1 cells resistance to Fas-mediated
apoptosis (Figure 11B & C). Western blotting analysis
indicated that LCL85 decreased xIAP protein levels in
both Colon 26 and 4 T1 cells (Figure 11D).Toxicity of LCL85
We analyzed serum enzyme profiles to determine
LCL85 liver toxicity. Analysis of serum enzyme/protein
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Figure 9 LCL85 treatment decreases Bcl-xL protein levels in metastatic human colon and mammary carcinoma cells. A & B. Metastatic
human colon (A) and mammary (B) carcinoma cells were treated with LCL85 at the indicated doses for approximately 24 h and analyzed for the
indicated proteins by Western blotting analysis.
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in mouse serum in a dose-dependent manner, and an
almost 3 fold ALT increase was detected at the highest
LCL85 dose examined (5 mg/kg body weight). No other
serum enzymes and proteins were significantly elevated
by LCL85 (Table 1).
LCL85 suppresses colon carcinoma metastatic potential in
an experimental lung metastasis mouse model in vivo
To determine the efficacy of LCL85 in suppression of me-
tastasis in vivo, we used an experimental metastasis mouse
model. Colon26 cells, a highly metastatic colon carcinoma
cell line, were injected i.v. to mice. Tumor-bearing mice
were treated with LCL85 over time. Lung metastasis was
then analyzed. LCL85 significantly suppressed colon26 lung
metastasis in a dose-dependent manner (Figure 12A & B).
Although LCL85 possesses direct anti-tumor cytotox-
icity (Figure 1) that might contribute to the observed
tumor suppression, it is possible that LCL85 might also
sensitize the tumor cells to apoptosis induction by FasL
of host immune cells, particularly CD8+ CTLs. We then
dissected tumor-bearing lungs and made single cell
suspension with collagenase. Staining cells with CD8-
and FasL-specific mAbs revealed that CD8+ T cells in
tumor-free mice are essentially FasL-. In contrast, ap-
proximately 31% of tumor-infiltrating CD8+ T cells are
FasL+ (Figure 12C). CD8+ cells in tumor-free mice are
all FasL- (Figure 12D). Therefore, LCL85 might sensitize
colon carcinoma cells to host FasL+ CTL-mediated
tumor suppression.
LCL85 suppresses spontaneous breast cancer metastasis
in vivo
To further determine the function of LCL85 in suppres-
sion of cancer metastasis, we used a complimentary breastcancer lung metastasis mouse model. Murine breast
cancer 4 T1 cells were injected to the mammary fat pad.
Tumor-bearing mice were treated with LCL85 over time
and both primary tumor growth and lung metastasis were
examined. LCL85 significantly suppressed the primary
mammary tumor growth in vivo as measured by tumor
size and tumor weight (Figure 13A). Interestingly, the
spontaneous lung metastasis was also significantly sup-
pressed by LCL85 (Figure 13B). The observation that
LCL85 suppresses spontaneous breast cancer lung me-
tastasis is significant. However, it is possible that the
decreased lung metastasis (Figure 13B) was due to the
decreased primary tumor growth (Figure 13A). To deter-
mine whether LCL85 directly suppresses spontaneous
metastasis, 4 T1 cells were injected to mouse mammary
fat pad. Primary tumors were surgically removed 15 days
after tumor cell injection. Mice were treated with LCL85
over time after surgery. This procedure thus mimics
human breast cancer patient treatment. Analysis of lungs
indicated that LCL85 significantly suppresses breast can-
cer spontaneous lung metastasis (Figure 13C & D). Taken
together, our data demonstrated that LCL85 at a subtoxic
dose is effective in suppression of colon and breast cancer
metastasis.Discussion
Ceramide mediates apoptosis through multiple mecha-
nisms. It has been reported that ceramide mediates Fas
receptor clustering, capping and activation to promote
Fas-mediated apoptosis [21-23]. Ceramide has also been
shown to regulate Bcl-x alternative splicing to decrease
Bcl-xL level [38], and mediates Bak, Bax and Bcl-2
functions in the intrinsic apoptosis pathway [39-43]. The
effects of ceramide on these apoptosis mediators are
apparently cell type- or cellular context-dependent since
Control LCL85  BV6 LCL85+BV6
FasL LCL85+FasL BV6+FasL LCL85+BV6+FasL
Control LCL85  BV6 LCL85+BV6
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Figure 10 Ceramide analog and Smac mimetic exhibit additive effects in sensitization of metastatic human colon carcinoma cells to
Fas-mediated apoptosis. A & B. SW620 (A) and LS411N (B) cells were cultured in the presence of LCL85 (5 μM), BV6 (5 μM), FasL (250 ng/ml),
and the combinations as indicated for approximately 24 h. Cells were stained with Annexin V and PI and analyzed by flow cytometry. Apoptotic
cell death for each treatment was indicated at the top right corner of each plot. Percentage of FasL-induced cell death is calculated by the
formula: % Annexin V+ and PI+ cells in the presence of FasL- % Annexin V+ and PI+ cells in the absence of FasL, and presented at the right.
Paschall et al. BMC Cancer 2014, 14:24 Page 12 of 17
http://www.biomedcentral.com/1471-2407/14/24LCL85 only alters the expression level of Bcl-xL in human
colon and breast cancer cells. Here, we identified xIAP
and cIAP1 as targets of the ceramide signaling pathways
in both metastatic human colon and breast cancer cells.
We observed that LCL85 effectively decreased cIAP1 and
xIAP protein levels in metastatic human colon and breast
cancer cells. Consistent with the decreased xIAP1 and
cIAP1 protein levels, metastatic human colon carcinoma
cells exhibited increased sensitivity to FasL-induced apop-
tosis. Furthermore, treatment of metastatic human colon
carcinoma cells with cIAP1 and xIAP-specific inhibitor
BV6 also significantly increased tumor cell sensitivity to
FasL-induced apoptosis [44]. Therefore, our data suggestthat xIAP1 and cIAP1 proteins are responsible, at least in
part, for the apoptosis-resistant phenotype in metastatic
human colon and breast cancers, and LCL85 overcomes
metastatic human colon and breast cancer cell resistance
to Fas-mediated apoptosis at least partially through indu-
cing proteasomal degradation of xIAP and cIAP1 proteins.
It has been well-documented that Smac mimetic BV6
specifically targets cIAP1 and cIAP2 proteins to induce
apoptosis through activating the TNFα signaling pathway
[36,45]. However, it has also been shown that xIAP,
rather than cIAP1 and cIAP2, is the critical target of BV6
in Fas-mediated apoptosis [44,46]. Strikingly, we observed
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Figure 11 LCL85 treatment decreases xIAP protein levels in mouse tumor cells. A & B. Colon 26 (A) and 4 T1 (B) cells were cultured in the
absence or presence of LCL85 (10 μM) and FasL (Colon 26 = 250 ng/ml; 4 T1 = 24 ng/ml) as indicated for 48 h. Cells were then stained with
Annexin V and PI and analyzed by flow cytometry. The apoptotic cell death is indicated at the top right corner of each plot. C: Quantification of
apoptosis. % FasL-induced cell death is calculated by the formula: % Annexin V+ and PI+ cells in the presence of FasL - % Annexin V+ and PI+ cells
in the absence of FasL. D. Colon 26 and 4 T1 cells were cultured in the absence or presence of LCL85 (10 μM) for approximately 24 h and
analyzed by Western blotting for xIAP protein level. β-actin was used as a normalization control.
Table 1 Mouse serum toxicity profiles of LCL85*
Treatment
Serum enzyme/protein level LCL85 (mg/kg body weight)
Control (n = 2) 1 (n = 4) 5 (n = 3)
ALP (U/L) 65 ± 7.1 67.5 ± 11.6 66.7 ± 5.1
ALT (U/L) 20.5 ± 4.9 37.8 ± 10.2 57.3 ± 24.2
GGT (U/L) <3.0 <3.0 <3.0
Albumin (g/dl) 3.2 ± 0.1 3.1 ± 0.1 3.2 ± 0.2
Glucose (mg/dl) 205 ± 29.7 198.5 ± 48.7 176.7 ± 23
Sodium (mmol/L) 150.5 ± 0.7 152.3 ± 2.2 151 ± 3
Potassium (mmol/L) 5.2 ± 0.1 6.4 ± 1 6.9 ± 0.5
Chloride (mmol/L) 108.5 ± 0.7 111 ± 2.6 111.7 ± 2.9
Bicarbonate (mmol/L) 16 ± 0 14.3 ± 2.2 15.7 ± 2.1
Anion Gap (mmol/L) 31 ± 0 33.5 ± 4.2 30.7 ± 2.5
Calcium ((mg/dl) 10.3 ± 0.1 10.2 ± 0.6 9.9 ± 0.3
Phosphorous (mg/dl) 8.8 ± 3.7 9.2 ± 1.9 8.5 ± 0.5
Cholesterol (mg/dl) 74.5 ± 9.2 68.8 ± 12.4 86 ± 4.6
UreaNitrogen (mg/dl) 24.5 ± 3.5 29.3 ± 4 26.3 ± 1.5
Total Bilirubin (mg/dl) 0.1 ± 0 0.1 ± 0 0.1 ± 0
Total Protein (g/dl) 4.5 ± 0.1 4.5 ± 0.3 4.8 ± 0.2
*Measurements were performed 3 days after LCL85 injection.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase.
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Figure 12 LCL85 suppresses colon carcinoma cell metastatic
potential in vivo. A. Colon26 cells were injected i.v. into mice.
Tumor-bearing mice were treated with LCL85 at the indicated doses
every 3 days for a total of 4 times. Mice were sacrificed and examined
for lung metastases nodules. Shown are tumor-bearing lungs from one
of two experiments. B. The number of lung tumor nodules are
enumerated and shown. Each dot represents total counts from a single
mouse. Counts greater than 250 are expressed as >/= 250. The horizontal
lines in the plot box represent mean tumor nodule numbers. C. Analysis
of FasL+ cells in tumor-bearing lungs. Single cell suspensions were
prepared from lungs of tumor-bearing mice as shown in A, stained with
CD8- and FasL-specific mAbs and analyzed by flow cytometry. IgG
isotype was used as a negative control (left panel). CD8+ T cells (middle
panel), FasL + and CD8+ T cells (right panel) are indicated in each plot.
Shown are representative results of 1 from 3 mice. D. Analysis of FasL+
cells in lungs of tumor-free mice. Single cell suspensions were prepared
from lungs of tumor-free mice, stained with CD8- and FasL-specific mAbs
and analyzed by flow cytometry. IgG isotype was used as a negative
control (left panel). FasL + and CD8+ T cells (right panel) are indicated in
each plot. Shown are representative results from 1 of 4 mice.
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http://www.biomedcentral.com/1471-2407/14/24apoptosis through inducing proteasomal degradation of
xIAP. LCL85 treatment increased endogenous C16 cer-
amide level and exogenous C16 ceramide is effective in
sensitizing the apoptotic resistant metastatic human colon
carcinoma cells to Fas-mediated apoptosis. Therefore, it
is possible that LCL85 sensitizes tumor cells to Fas-
mediated apoptosis at least in part through inducing C16
ceramide accumulation, resulting in ceramide-mediated
xIAP and cIAP1 proteasomal degradation. However, the
molecular mechanisms underlying the crosstalk network
between ceramide analog, C16 ceramide and IAP proteins
remain to be elucidated.
Ceramide analog-mediated direct cytotoxicity often
depends on administering a high dose of the agent
[47]. In this study, LCL85 exhibited potent anti-tumor
cytotoxicity, suggesting that LCL85 is potentially an
effective therapeutic agent in cancer therapy. However,
LCL85 also exhibited toxicity in a dose-dependent
manner. Therefore, LCL85 might also be toxic if used
in high doses. Interestingly, we demonstrated that a
sublethal dose of LCL85 is not cytotoxic but effectively
sensitizes metastatic human colon carcinoma cells to
FasL-induced apoptosis in vitro. This observation is
significant since a sublethal dose of LCL85 might be
safe and yet an effective sensitizer in FasL+ CTL-based
cancer immunotherapy.
Tumor-reactive CTLs primarily use the perforin and
Fas/FasL effector mechanisms to induce target tumor
cell apoptosis. Immunosuppression of CTL activation
and effector functions by immuno- suppressive cells is a
major challenge in cancer immunotherapy. However,
recent studies revealed that the immuno- suppressive
Treg cells only selectively suppress the perforin pathway
without inhibiting CTL activation and proliferation
in vivo [48,49], suggesting that Treg cells may not
suppress the Fas/FasL effector mechanism of CTL
in vivo. Indeed, our recent study showed that tumor-
infiltrating CTLs in tumor-bearing mice and CTLs from
human colon and breast cancer patients are FasL+ [32].
Therefore, the Fas/FasL effector mechanism might be
functional in the immuno suppressive tumor microenvir-
onment. However, metastatic human colon and breast
cancer cells are often resistant to Fas-mediated apoptosis
[8,9]. Therefore, a therapeutic agent that can sensitize
tumor cell Fas resistance may represent an effective
enhancer of CTL-based cancer immunotherapy against
metastatic colon and breast cancers. Our data suggest
that LCL85 is potentially such an agent. Although
LCL85 does not effectively sensitize Colon 26 cells to
FasL-induced apoptosis, LCL85 is effective in suppress-
ing Colon 26 cell metastatic potential in vivo, suggesting
that other host factors, such as IFN-γ and TNFα se-
creted by T cells, might also act to sensitize the tumor
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Figure 13 Ceramide analog suppresses breast cancer growth
and spontaneous lung metastasis. A. LCL85 suppresses breast
cancer growth and metastasis. 4 T1 cells were injected to the
mammary fat pad of mice. Tumor bearing mice were treated with
LCL85 (2.5 mg/kg body weight) through i.v. injection. Tumor sizes
were recorded and presented at the bottom left panel. The tumors
were also dissected and weighed and presented at the bottom right
panel. Column, mean; bar, SD. B. Lungs of tumor-bearing mice as in A
were analyzed for tumor nodules. The white spots are tumor nodules
and the black tissues are normal lung tissues. Shown are images of
representative tumor-bearing lungs. The tumor nodules in each lung
were enumerated and presented at the right panel. Column, mean;
bar, SD. C. LCL85 suppresses spontaneous breast cancer metastasis.
4 T1 cells were transplanted to the mammary fat pads of mice. Primary
tumors were surgically removed 15 days later. Mice were treated with
LCL85 (2.5 mg/kg body weight) at days 8, 11, 14 and 17 after surgery.
Lungs were analyzed for metastasis at day 19 after surgery. Shown are
tumor-bearing lungs. D. The tumor nodules were enumerated. Each
dot represents total tumor nodule number of a mouse lung.
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We envision that a sublethal dose of LCL85 can be used
as a sensitizer in cancer immunotherapy for metastatic
colon and breast cancers. This idea is analogous
to a “one-two punch” concept. First, cancer patients
are treated with a non-cytotoxic dose of LCL85 to
sensitize cancer cells to apoptosis. Once “sensitized”,
patients are then treated with FasL+ CTLs-based
immunotherapy to suppress cancer metastasis. Our
in vivo tumor suppression studies showed that
low doses (2.5-5 mg/kg body weight) of LCL85 exhib-
ited potent tumor suppression activity in immune-
competent mice in vivo (Figure 12). A previous
study showed that lack of ceramide accumulation in
target cells is a significant cause of resistance to cyto-
toxic T lymphocyte (CTL)-induced apoptosis [50]. In
this study, we observed that a large portion of the
tumor-infiltrating CTLs are FasL+ (Figure 12C), and
low doses of LCL85 effectively suppresses colon and
breast tumor growth and metastasis in immune-
competent mice (Figures 12 & 13). Our observations
thus indicate that LCL85 might sensitize tumor cells
to CTL-induced apoptosis through inducing ceramide
accumulation in the tumor cells in vivo, which
requires further investigation. Nevertheless, our data
suggest that LCL85, although effective as a single
agent in suppression of tumor development at high
doses, might be more valuable if used at a sublethal
dose as a sensitizer for enhancing the efficacy of FasL-
based cancer therapy, particularly CTL-based cancer
immunotherapy.Competing interests
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